Genentech (S. San Francisco, CA) has announced disappointing phase II trial results of its anti-CD18 monoclonal antibodies in treating heart attacks. Preliminary analysis of the data in June ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback